Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Day One Biopharmaceuticals, Inc. (DAWN)

21.555   0.105 (0.49%) 12-06 09:58
Open: 21.13 Pre. Close: 21.45
High: 21.555 Low: 21.09
Volume: 11,736 Market Cap: 1,585(M)

Technical analysis

as of: 2022-12-06 9:47:03 AM
Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 26.98     One year: 31.51
Support: Support1: 20.25    Support2: 18.48
Resistance: Resistance1: 23.1    Resistance2: 26.98
Pivot: 21.17
Moving Average: MA(5): 21.38     MA(20): 21.01
MA(100): 21.09     MA(250): 16.08
MACD: MACD(12,26): 0.2     Signal(9): 0.2
Stochastic oscillator: %K(14,3): 56.4     %D(3): 61.2
RSI: RSI(14): 52.9
52-week: High: 28.35  Low: 5.44
Average Vol(K): 3-Month: 595 (K)  10-Days: 341 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ DAWN ] has closed below upper band by 44.5%. Bollinger Bands are 59% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 23.13 - 23.25 23.25 - 23.35
Low: 20.74 - 20.85 20.85 - 20.95
Close: 21.28 - 21.46 21.46 - 21.61

Company Description

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Headline News

Tue, 06 Dec 2022
Islamabad's Centaurus Mall partially de-sealed - Pakistan - DAWN.COM -

Tue, 06 Dec 2022
Cryptoverse: Forget crypto winter, this is a bitcoin 'bloodbath' -

Tue, 06 Dec 2022
Obituary: Dawn Marie Kitchin - - Kennebec Journal and Morning Sentinel

Mon, 05 Dec 2022
Is renaissance a possibility? - Newspaper - DAWN.COM -

Mon, 05 Dec 2022
Gold price hits record Rs164k per tola - Business - DAWN.COM -

Mon, 05 Dec 2022
Auto financing drops for fourth consecutive month - Business - DAWN.COM -

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 74 (M)
Shares Float 37 (M)
% Held by Insiders 29.5 (%)
% Held by Institutions 77 (%)
Shares Short 5,040 (K)
Shares Short P.Month 5,980 (K)

Stock Financials

EPS 5.5
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 4.94
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -23
Return on Equity (ttm) -37.6
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -1.72
Qtrly Earnings Growth 0
Operating Cash Flow -88 (M)
Levered Free Cash Flow -41 (M)

Stock Valuations

PE Ratio 3.86
PEG Ratio 0
Price to Book value 4.3
Price to Sales 0
Price to Cash Flow -17.85

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.